This includes 29 patients with breast cancer (14 tested positive for HER2), 13 with malignant melanoma (5 tested positive for the BRAF-V600E mutation), 1 with NSLSC (no PD-L-1 mutation), and 1 with esophagus cancer (no PD-L-1 mutation). This evidence concerns the gene ERBB2 and melanoma.